ArticleBioinformatics (Oxford, England)2025
EpicPred: predicting phenotypes driven by epitope-binding TCRs using attention-based multiple instance learning.
Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- PU-GRAIL: residue-level graph learning for identifying protective bacterial antigens under positive-unlabeled supervision.Bioinformatics (Oxford, England) · 2026Article
- Modeling TCR-Epitope Recognition Specificity: What We Should Learn to Succeed.Immunological reviews · 2026Review
- Decoding immunotherapy response through computational modeling.Nature communications · 2026Review
- AI-driven discovery in protein science for immunology and infectious disease research.Frontiers in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
motivationCorrectly identifying epitope-binding T-cell receptors (TCRs) is important to both understand their underlying biological mechanism in association to some phenotype and accordingly develop T-cell mediated immunotherapy treatments. Although the importance of the CDR3 region in TCRs for epitope recognition is well recognized, methods for profiling their interactions in association to a certain disease or phenotype remains less studied. We developed EpicPred to identify phenotype-specific TCR-epitope interactions. EpicPred first predicts and removes unlikely TCR-epitope interactions to reduce false positives using the Open-set Recognition (OSR). Subsequently, multiple instance learning was used to identify TCR-epitope interactions specific to a cancer type or severity levels of COVID-19 infected patients.
resultsFrom six public TCR databases, 244 552 TCR sequences and 105 unique epitopes were used to predict epitope-binding TCRs and to filter out non-epitope-binding TCRs using the OSR method. The predicted interactions were used to further predict the phenotype groups in two cancer and four COVID-19 TCR-seq datasets of both bulk and single-cell resolution. EpicPred outperformed the competing methods in predicting the phenotypes, achieving an average AUROC of 0.80 ± 0.07. AVAILABILITY AND IMPLEMENTATION: The EpicPred Software is available at https://github.com/jaeminjj/EpicPred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.